Medera Inc., a clinical-stage biopharmaceutical company, announced that data from its Phase 1/2a MUSIC-HFpEF clinical trial investigating its gene therapy candidate SRD-002 for heart failure with preserved ejection fraction (HFpEF) will be presented at the Heart Failure 2025 Congress. The trial is studying SRD-002, a one-time gene therapy delivered via a minimally invasive intracoronary infusion. Dr. Marat Fudim of Duke University Medical Center will present the findings on May 18th.
This research is crucial because HFpEF represents a significant portion of heart failure cases globally, and current treatment options are limited in their disease-modifying effects. Successful clinical data for SRD-002 could pave the way for a new therapeutic approach, offering a potential one-time treatment option that directly addresses the underlying causes of HFpEF. This could significantly improve the quality of life for patients and reduce the strain on healthcare systems currently managing this chronic condition.
The MUSIC-HFpEF trial is evaluating a novel, adeno-associated virus-based gene therapy delivered through a proprietary intracoronary infusion method. This approach is designed to directly target the heart muscle, potentially offering a more effective and durable treatment compared to existing therapies. Medera has previously received Investigational New Drug (IND) clearance from the FDA for this trial and holds Fast Track Designation for SRD-002 in HFpEF. Medera has also entered into a definitive merger agreement with Keen Vision Acquisition Corporation (KVAC), suggesting a potential pathway to public markets and further funding for development.
Positive data from the MUSIC-HFpEF trial could transform the HFpEF treatment landscape. It may also validate Medera’s gene therapy platform and position the company as a leader in cardiovascular disease treatment, potentially attracting further investment and accelerating the development of other pipeline candidates. This presentation at the Heart Failure 2025 Congress represents a critical step in bringing this promising therapy to patients.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
